Evidence map›Paper›PMID 39254909›Full record

ArticleImmunologic research2024

Changes in immune subsets during chemotherapy as prognosis biomarkers for multiple myeloma patients by longitudinal monitoring.

Pengcheng Xu, Ying Li, Xibing Zhuang, Lei Yue, Yanna Ma, Wenjin Xue, Lili Ji, Yanxia Zhan, Yang Ou, Tiankui Qiao and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Pengcheng Xu *Center for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Ying Li *Center for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Xibing Zhuang *Center for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Lei Yue *Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai, China.
Yanna MaCenter for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Wenjin XueCenter for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Lili JiDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yanxia ZhanDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yang OuCenter for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Tiankui QiaoCenter for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Duojiao WuCenter for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Peng LiuDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China. liu.peng@zs-hospital.sh.cn.
Hao ChenCenter for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Yunfeng ChengCenter for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.

Funding

Key Subject Construction Program of Shanghai Health Administrative Authority ZK2019B30Postdoctoral Fellowship Program of CPSF GZ2023509Shanghai Academic/Technology Researcher leader 20XD1401000Shanghai Engineering Research Center of Tumor Multi-Target Gene Diagnosis 20DZ2254300three-year plan for Center for Tumor Diagnosis & Therapy, Jinshan Hospital XKPT-2020-1Youth Start-up Fund of Jinshan hospital JYQN-JC-202102, JYQN-JC-202305 and JYQN-JC-202005
6 · The paper itself

Abstract

Multiple myeloma (MM) is a malignancy of plasma cells accompanied by immune dysfunction. This study aimed to provide a comprehensive and dynamic characterization of the peripheral immune environment in MM patients and find its diagnostic and prognostic values for therapy. The peripheral immune profiles of MM inpatients and healthy controls were assessed by flow cytometry. A longitudinal study of immune subsets was observed during cycles of chemotherapy. The diagnostic and prognostic models were established based on immune subsets by the absolute shrinkage and selection operator (LASSO) and multivariate regression. MM patients possessed an impeded immune landscape, including reduced activation of B cells, increased effective T cells and regulatory T cells (Tregs), augmented CD16 expression on monocytes and dendritic cell percentages, decreased CD56

Indexed as

Multiple MyelomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBiomarkers, TumorDendritic CellsFemaleHumansImmunophenotypingKiller Cells, NaturalLongitudinal StudiesMaleMiddle AgedPrognosisBiomarkersBiomarkers, TumorAdaptive immunityImmune subsetsInnate immunityMultiple myelomaPrognostic factors

Identifiers

PMID39254909

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.